Tuberculosis — Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates
Citation(s)
Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region